Does the media favor COGT or ROIV?

In the previous week, Roivant Sciences had 11 more articles in the media than Cogent Biosciences. MarketBeat recorded 15 mentions for Roivant Sciences and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.71 beat Roivant Sciences' score of 1.34 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Roivant Sciences 11 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer COGT or INSM?

In the previous week, Insmed had 19 more articles in the media than Cogent Biosciences. MarketBeat recorded 23 mentions for Insmed and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.71 beat Insmed's score of 1.07 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insmed 13 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to BNTX or COGT?

In the previous week, BioNTech had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 9 mentions for BioNTech and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.71 beat BioNTech's score of 0.97 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Is VTRS or COGT more profitable?

Cogent Biosciences has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Viatris -2.04% 19.04% 7.62% Cogent Biosciences N/A -104.27% -54.64%

Does the media favor VTRS or COGT?

In the previous week, Viatris and Viatris both had 4 articles in the media. Cogent Biosciences' average media sentiment score of 1.71 beat Viatris' score of 0.47 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viatris 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cogent Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to COGT or GMAB?

In the previous week, Genmab A/S had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 6 mentions for Genmab A/S and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.71 beat Genmab A/S's score of 1.03 indicating that Cogent Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cogent Biosciences (COGT) Competitors

$39.76 -0.48 (-1.19%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$39.76 0.00 (-0.01%)

As of 07/24/2026 07:34 PM Eastern

Compare

COGT vs. ROIV, INSM, BNTX, VTRS, and GMAB

Should you buy Cogent Biosciences stock or one of its competitors? MarketBeat compares Cogent Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cogent Biosciences include Roivant Sciences (ROIV), Insmed (INSM), BioNTech (BNTX), Viatris (VTRS), and Genmab A/S (GMAB). These companies are all part of the "pharmaceutical products" industry.

How does Cogent Biosciences compare to Roivant Sciences?

Cogent Biosciences (NASDAQ:COGT) and Roivant Sciences (NASDAQ:ROIV) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.11, suggesting that its share price is 11% more volatile than the broader market.

In the previous week, Roivant Sciences had 11 more articles in the media than Cogent Biosciences. MarketBeat recorded 15 mentions for Roivant Sciences and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.71 beat Roivant Sciences' score of 1.34 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Roivant Sciences	11 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Roivant Sciences	-3,629.19%	-20.54%	-19.43%

Cogent Biosciences currently has a consensus price target of $45.90, indicating a potential upside of 15.44%. Roivant Sciences has a consensus price target of $33.59, indicating a potential downside of 4.05%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Cogent Biosciences is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

64.8% of Roivant Sciences shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 10.8% of Roivant Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Roivant Sciences has higher revenue and earnings than Cogent Biosciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Roivant Sciences	$8.26M	3,048.63	-$299.77M	-$0.60	N/A

Summary

Roivant Sciences beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Insmed?

Cogent Biosciences (NASDAQ:COGT) and Insmed (NASDAQ:INSM) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

Cogent Biosciences has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Insmed	$606.42M	38.22	-$1.28B	-$5.75	N/A

Cogent Biosciences has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Insmed has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

In the previous week, Insmed had 19 more articles in the media than Cogent Biosciences. MarketBeat recorded 23 mentions for Insmed and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.71 beat Insmed's score of 1.07 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Insmed	13 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Cogent Biosciences has a net margin of 0.00% compared to Insmed's net margin of -144.44%. Cogent Biosciences' return on equity of -104.27% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Insmed	-144.44%	-130.11%	-51.57%

Cogent Biosciences currently has a consensus price target of $45.90, indicating a potential upside of 15.44%. Insmed has a consensus price target of $209.13, indicating a potential upside of 95.60%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Insmed beats Cogent Biosciences on 7 of the 13 factors compared between the two stocks.

How does Cogent Biosciences compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

15.5% of BioNTech shares are held by institutional investors. 19.2% of BioNTech shares are held by insiders. Comparatively, 6.6% of Cogent Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, BioNTech had 5 more articles in the media than Cogent Biosciences. MarketBeat recorded 9 mentions for BioNTech and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.71 beat BioNTech's score of 0.97 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cogent Biosciences has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Cogent Biosciences	N/A	-104.27%	-54.64%

BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market.

Cogent Biosciences has lower revenue, but higher earnings than BioNTech. Cogent Biosciences is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.81B	8.05	-$1.29B	-$5.88	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

BioNTech presently has a consensus target price of $129.13, indicating a potential upside of 44.55%. Cogent Biosciences has a consensus target price of $45.90, indicating a potential upside of 15.44%. Given BioNTech's higher probable upside, equities analysts clearly believe BioNTech is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

Summary

BioNTech beats Cogent Biosciences on 10 of the 16 factors compared between the two stocks.

How does Cogent Biosciences compare to Viatris?

Viatris (NASDAQ:VTRS) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Viatris currently has a consensus target price of $17.50, indicating a potential upside of 1.51%. Cogent Biosciences has a consensus target price of $45.90, indicating a potential upside of 15.44%. Given Cogent Biosciences' stronger consensus rating and higher possible upside, analysts clearly believe Cogent Biosciences is more favorable than Viatris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viatris	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85

In the previous week, Viatris and Viatris both had 4 articles in the media. Cogent Biosciences' average media sentiment score of 1.71 beat Viatris' score of 0.47 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viatris	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cogent Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cogent Biosciences has lower revenue, but higher earnings than Viatris. Viatris is trading at a lower price-to-earnings ratio than Cogent Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viatris	$14.56B	1.38	-$3.51B	-$0.26	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

Cogent Biosciences has a net margin of 0.00% compared to Viatris' net margin of -2.04%. Viatris' return on equity of 19.04% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viatris	-2.04%	19.04%	7.62%
Cogent Biosciences	N/A	-104.27%	-54.64%

Viatris has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

79.9% of Viatris shares are owned by institutional investors. 0.3% of Viatris shares are owned by company insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Cogent Biosciences beats Viatris on 9 of the 15 factors compared between the two stocks.

How does Cogent Biosciences compare to Genmab A/S?

Cogent Biosciences (NASDAQ:COGT) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, profitability, media sentiment, earnings, dividends, analyst recommendations and institutional ownership.

Cogent Biosciences presently has a consensus price target of $45.90, suggesting a potential upside of 15.44%. Genmab A/S has a consensus price target of $39.28, suggesting a potential upside of 36.05%. Given Genmab A/S's higher possible upside, analysts plainly believe Genmab A/S is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	2.85
Genmab A/S	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77

Cogent Biosciences has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than Cogent Biosciences. Cogent Biosciences is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Genmab A/S	$3.72B	4.84	$963M	$1.32	21.87

In the previous week, Genmab A/S had 2 more articles in the media than Cogent Biosciences. MarketBeat recorded 6 mentions for Genmab A/S and 4 mentions for Cogent Biosciences. Cogent Biosciences' average media sentiment score of 1.71 beat Genmab A/S's score of 1.03 indicating that Cogent Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Genmab A/S has a net margin of 21.05% compared to Cogent Biosciences' net margin of 0.00%. Genmab A/S's return on equity of 15.34% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Genmab A/S	21.05%	15.34%	8.94%

7.1% of Genmab A/S shares are owned by institutional investors. 6.6% of Cogent Biosciences shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Genmab A/S beats Cogent Biosciences on 12 of the 16 factors compared between the two stocks.

Get Cogent Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding COGT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

COGT vs. The Competition

Export

Metric	Cogent Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.88B	$3.67B	$6.88B	$12.26B
Dividend Yield	N/A	2.19%	2.67%	9.80%
P/E Ratio	-18.32	21.11	26.99	23.71
Price / Sales	N/A	165.25	492.47	76.53
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	10.35	7.88	10.28	6.07
Net Income	-$328.94M	$23.81M	$3.60B	$331.84M
7 Day Performance	1.74%	-3.79%	-1.25%	-1.53%
1 Month Performance	4.60%	-2.59%	-0.35%	-2.46%
1 Year Performance	229.41%	32.85%	18.41%	13.66%

Cogent Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
COGT Cogent Biosciences	1.959 of 5 stars	$39.76 -1.2%	$45.90 +15.4%	+226.2%	$6.88B	N/A	N/A	80	News Coverage Positive News
ROIV Roivant Sciences	1.6656 of 5 stars	$34.51 -4.1%	$33.59 -2.7%	+207.6%	$25.87B	$8.26M	N/A	860	News Coverage
INSM Insmed	3.8933 of 5 stars	$109.14 -5.6%	$211.00 +93.3%	+3.3%	$25.06B	$606.42M	N/A	1,664	Positive News
BNTX BioNTech	4.1874 of 5 stars	$90.07 -1.6%	$129.13 +43.4%	-22.0%	$23.14B	$3.25B	N/A	7,807
VTRS Viatris	2.5529 of 5 stars	$16.39 +0.7%	$17.50 +6.8%	+84.4%	$18.95B	$14.30B	N/A	30,000	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:COGT) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cogent Biosciences (COGT) Competitors

COGT vs. ROIV, INSM, BNTX, VTRS, and GMAB

How does Cogent Biosciences compare to Roivant Sciences?

Summary

How does Cogent Biosciences compare to Insmed?

Summary

How does Cogent Biosciences compare to BioNTech?

Summary

How does Cogent Biosciences compare to Viatris?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cogent Biosciences (COGT) Competitors

COGT vs. ROIV, INSM, BNTX, VTRS, and GMAB

How does Cogent Biosciences compare to Roivant Sciences?

Which has more volatility & risk, COGT or ROIV?

Does the media favor COGT or ROIV?

Is COGT or ROIV more profitable?

Do analysts recommend COGT or ROIV?

Do insiders and institutionals believe in COGT or ROIV?

Which has higher earnings and valuation, COGT or ROIV?

Summary

How does Cogent Biosciences compare to Insmed?

Which has stronger valuation & earnings, COGT or INSM?

Which has more volatility & risk, COGT or INSM?

Does the media prefer COGT or INSM?

Is COGT or INSM more profitable?

Do analysts recommend COGT or INSM?

Summary

How does Cogent Biosciences compare to BioNTech?

Do insiders and institutionals believe in BNTX or COGT?

Does the media refer more to BNTX or COGT?

Is BNTX or COGT more profitable?

Which has more risk & volatility, BNTX or COGT?

Which has stronger earnings & valuation, BNTX or COGT?

Do analysts prefer BNTX or COGT?

Summary

How does Cogent Biosciences compare to Viatris?

Do analysts rate VTRS or COGT?

Does the media favor VTRS or COGT?

Which has stronger earnings and valuation, VTRS or COGT?

Is VTRS or COGT more profitable?

Which has more risk & volatility, VTRS or COGT?

Do insiders & institutionals believe in VTRS or COGT?

Summary

How does Cogent Biosciences compare to Genmab A/S?

Do analysts prefer COGT or GMAB?

Which has more risk & volatility, COGT or GMAB?

Which has higher earnings & valuation, COGT or GMAB?

Does the media refer more to COGT or GMAB?

Is COGT or GMAB more profitable?

Do insiders and institutionals hold more shares of COGT or GMAB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT vs. The Competition

Cogent Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools